In a report released yesterday, Mark Massaro from BTIG maintained a Hold rating on CareDx (CDNA – Research Report). The company’s shares closed last Friday at $12.00.
Massaro covers the Healthcare sector, focusing on stocks such as Guardant Health, Personalis, and SOPHiA GENETICS. According to TipRanks, Massaro has an average return of -15.6% and a 33.00% success rate on recommended stocks.
Currently, the analyst consensus on CareDx is a Hold with an average price target of $10.00.
See the top stocks recommended by analysts >>
CDNA market cap is currently $649.2M and has a P/E ratio of -7.13.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CareDx (CDNA) Company Description:
CareDx, Inc. operates as a transplant diagnostics company,which discovers, develops, and commercializes diagnostic solutions. Its product includes AlloMap, AlloSure, and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.
Read More on CDNA:
